Christos E. Kyriakopoulos

5.3k total citations · 2 hit papers
84 papers, 2.0k citations indexed

About

Christos E. Kyriakopoulos is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Christos E. Kyriakopoulos has authored 84 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 47 papers in Oncology and 21 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Christos E. Kyriakopoulos's work include Prostate Cancer Treatment and Research (35 papers), Radiopharmaceutical Chemistry and Applications (20 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Christos E. Kyriakopoulos is often cited by papers focused on Prostate Cancer Treatment and Research (35 papers), Radiopharmaceutical Chemistry and Applications (20 papers) and Cancer Immunotherapy and Biomarkers (19 papers). Christos E. Kyriakopoulos collaborates with scholars based in United States, Greece and France. Christos E. Kyriakopoulos's co-authors include David F. Jarrard, Glenn Liu, Jorge A. García, Michael A. Carducci, Mario A. Eisenberger, Robert S. DiPaola, Joel Picus, Maha Hussain, Yu‐Hui Chen and Robert Dreicer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Christos E. Kyriakopoulos

76 papers receiving 1.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

2018 695 citations Christos E. Kyriakopoulos, Yu‐Hui Chen et al. Journal of Clinical Oncology profile →
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christos E. Kyriakopoulos United States	19	1.1k	780	405	392	386	84	2.0k
Benjamin L. Maughan United States	22	1.4k 1.2×	915 1.2×	294 0.7×	266 0.7×	541 1.4×	167	2.1k
Vincent van der Noort Netherlands	23	1.4k 1.3×	1.3k 1.6×	332 0.8×	286 0.7×	266 0.7×	133	2.5k
Pedro C. Barata United States	24	1.4k 1.3×	846 1.1×	233 0.6×	503 1.3×	993 2.6×	218	2.5k
Daniel L. Suzman United States	19	812 0.7×	1.3k 1.6×	219 0.5×	272 0.7×	352 0.9×	59	2.0k
Kathryn P. Gray United States	22	1.0k 0.9×	959 1.2×	152 0.4×	179 0.5×	622 1.6×	75	2.0k
Philipp Nuhn Germany	21	978 0.9×	433 0.6×	270 0.7×	367 0.9×	656 1.7×	104	1.8k
Sebastiano Buti Italy	26	1.2k 1.1×	1.1k 1.5×	96 0.2×	369 0.9×	690 1.8×	210	2.2k
Ulrika Harmenberg Sweden	23	1.0k 0.9×	736 0.9×	281 0.7×	208 0.5×	693 1.8×	57	1.7k
Julia Wilkerson United States	20	713 0.6×	608 0.8×	208 0.5×	188 0.5×	501 1.3×	44	1.8k
Yongli Shuai United States	27	521 0.5×	1.3k 1.7×	117 0.3×	345 0.9×	814 2.1×	48	2.7k

Countries citing papers authored by Christos E. Kyriakopoulos

Since Specialization

Citations

This map shows the geographic impact of Christos E. Kyriakopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christos E. Kyriakopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christos E. Kyriakopoulos more than expected).

Fields of papers citing papers by Christos E. Kyriakopoulos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christos E. Kyriakopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christos E. Kyriakopoulos. The network helps show where Christos E. Kyriakopoulos may publish in the future.

Co-authorship network of co-authors of Christos E. Kyriakopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of Christos E. Kyriakopoulos. A scholar is included among the top collaborators of Christos E. Kyriakopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christos E. Kyriakopoulos. Christos E. Kyriakopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McKay, Rana R., Wanling Xie, Archana Ajmera, et al.. (2025). A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.. Journal of Clinical Oncology. 43(16_suppl). 5007–5007. 1 indexed citations

Cole, Suzanne, Se Eun Kim, Andrew L. Wentland, et al.. (2025). Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).. Journal of Clinical Oncology. 43(5_suppl).

Kyriakopoulos, Christos E., Yu‐Hui Chen, Robert Jeraj, et al.. (2024). Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).. Journal of Clinical Oncology. 42(17_suppl). LBA5000–LBA5000. 2 indexed citations

Loriot, Yohann, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.. (2024). A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer. Future Oncology. 20(23). 1621–1631. 1 indexed citations

Pant, Shubham, Byoung Chul Cho, Christos E. Kyriakopoulos, et al.. (2024). Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Investigational New Drugs. 42(5). 547–558. 1 indexed citations

Lang, Joshua M., Susan F. Slovin, Jamie M. Sperger, et al.. (2024). 1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI). Annals of Oncology. 35. S993–S994. 1 indexed citations

Pan, Elizabeth, Wanling Xie, Archana Ajmera, et al.. (2023). A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE). Molecular Cancer Therapeutics. 22(4). 511–518. 29 indexed citations

Chatta, Gurkamal, Christos E. Kyriakopoulos, Nicholas Iannotti, et al.. (2023). 1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results. Annals of Oncology. 34. S982–S983. 4 indexed citations

Jani, Chinmay, Wanling Xie, Archana Ajmera, et al.. (2023). A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.. Journal of Clinical Oncology. 41(16_suppl). TPS5110–TPS5110.

10.

McNeel, Douglas G., Hamid Emamekhoo, Jens C. Eickhoff, et al.. (2023). Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer. Journal for ImmunoTherapy of Cancer. 11(12). e008067–e008067. 29 indexed citations

11.

Taylor, Amy K., Jamie M. Sperger, Marina N. Sharifi, et al.. (2023). Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.. Journal of Clinical Oncology. 41(6_suppl). 247–247. 1 indexed citations

12.

Kyriakopoulos, Christos E., et al.. (2022). ESTIA: a versatile platform for effective fire disaster management in cultural heritage sites and settlements. 44. 25–25. 1 indexed citations

13.

Thomopoulos, Stelios C. A. & Christos E. Kyriakopoulos. (2022). iCrowd simulation-as-a service (SaaS): a distributed and remotely accessible simulation platform. 9842. 27–27. 1 indexed citations

14.

Sperger, Jamie M., Susan F. Slovin, Scott T. Tagawa, et al.. (2021). TROP-2 co-expression with androgen receptor splice variants as a new therapeutic target in prostate cancer.. Journal of Clinical Oncology. 39(15_suppl). 5060–5060. 1 indexed citations

15.

Loriot, Yohann, Arjun Vasant Balar, Daniel P. Petrylak, et al.. (2021). 700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC). Annals of Oncology. 32. S712–S713. 5 indexed citations

16.

Kyriakopoulos, Christos E., Jens C. Eickhoff, Anna C. Ferrari, et al.. (2020). Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. Clinical Cancer Research. 26(19). 5162–5171. 47 indexed citations

17.

Loriot, Yohann, Arjun Vasant Balar, Daniel P. Petrylak, et al.. (2020). LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Annals of Oncology. 31. S1156–S1156. 19 indexed citations

18.

Sperger, Jamie M., Erika Héninger, Dharmesh Gopalakrishnan, et al.. (2017). Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.. Journal of Clinical Oncology. 35(15_suppl). 4537–4537. 5 indexed citations

19.

Blute, Michael L., Timothy J. Ziemlewicz, Joshua M. Lang, et al.. (2016). Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology. 100. 139–144. 5 indexed citations

20.

Christodoulopoulos, Christos, Christos E. Kyriakopoulos, & Αthanasios G. Kanatas. (2007). A realistic approach to source localization using a wireless robotic network. 46. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact